2/4
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
1/27
08:05 am
svra
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Low
Report
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
1/24
11:38 am
svra
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1/16
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
1/11
09:22 am
svra
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
Low
Report
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest [Yahoo! Finance]
1/8
04:27 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* [Yahoo! Finance]
1/8
04:05 pm
svra
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
Low
Report
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
12/23
10:13 am
svra
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
Low
Report
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
12/23
08:42 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/23
07:17 am
svra
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/22
09:05 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
12/22
08:30 am
svra
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Medium
Report
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
12/18
10:26 am
svra
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
Low
Report
Savara (NASDAQ:SVRA) had its price target raised by analysts at Wells Fargo & Company from $7.00 to $9.00. They now have an "overweight" rating on the stock.
12/17
08:05 am
svra
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
12/11
08:55 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
Low
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]
12/11
08:05 am
svra
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Medium
Report
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
12/2
02:41 pm
svra
Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]
Low
Report
Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]
12/2
08:05 am
svra
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Low
Report
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
11/20
04:05 pm
svra
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Medium
Report
Savara Announces Participation in Upcoming Investor Healthcare Conferences
11/16
06:36 am
svra
Savara: A High-Risk Opportunity [Seeking Alpha]
Low
Report
Savara: A High-Risk Opportunity [Seeking Alpha]
11/14
12:31 pm
svra
Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.
Low
Report
Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.
11/13
10:49 am
svra
Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.
Medium
Report
Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.
11/12
04:05 pm
svra
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update